BofA analyst Tazeen Ahmad lowered the firm’s price target on Annexon (ANNX) to $11 from $12 and keeps a Buy rating on the shares. The firm rolled the quarter, updated for Q4 results, cash and share count, and adjusted operating expense estimates based on management commentary.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANNX:
- Annexon Biosciences: Promising Developments and Strategic Milestones Justify Buy Rating
- Promising Developments in Annexon Biosciences’ Pipeline Drive Buy Rating
- Promising Potential of Annexon Biosciences’ ANX1502 Drives Buy Rating Amid Positive Clinical Data
- Annexon price target lowered to $20 from $30 at H.C. Wainwright
- Strategic Advancements and Financial Stability Drive Buy Rating for Annexon Biosciences